Severe eczema was a real challenge for this 3 year old and his mother until they added RCO or Real Cannabis Oil to his medicine.

This is the reality of what cannabis could do for many other children suffering with the exact same condition.

Most will never have that opportunity simply because they are not aware of this information.

Perhaps you would take the time to share this valuable information?

The first textbook of dermatologic therapeutics was also written by Piffard. In it he notes, “a pill of cannabis indica at bedtime has at my hands sometimes afforded relief to the intolerable itching of eczema.” Since then, there have been myriad studies published on the potential benefits of cannabinoids in skin conditions.

Many features of AD contribute to itch, particularly dry skin, histamine release and sensory nerve fibers. Cannabinoids, however, have a powerful anti-itch effect. There are receptors in the skin that interact with cannabinoids that could reduce the symptoms and appearance of AD. These effects happen through a constellation of interactions between phytocannabinoids and our endogenous cannabinoid system.

Another way cannabinoids hold promise as a treatment are through management of Staphylococcus aureus colonization, which is both a complication and a driving factor of AD.

The antimicrobial characteristics of cannabinoids have been referenced since the 1980s, but a more detailed analysis of individual cannabinoids found that all five major cannabinoids showed potent activity against a variety of S. aureus strains.

What does this mean? Cannabinoids have an anti-microbial effect, but more testing is needed to understand the risks and benefits of cannabinoids in dermatology.

Cannabinoids also exhibit anti-inflammatory properties. Researchers demonstrated that topical THC suppresses allergic contact dermatitis in mice by activating CB1 receptors. Other molecules, similar to those present in cannabis, have also demonstrated significant anti-pain properties in rat models.

There are reports of direct improvement of AD with topical cannabinoids. A recent study demonstrated that a molecule interacting with the endocannabinoid system inhibited mast cell activation. Mast cells are immune cells that release histamine when activated, which leads to intense itching and inflammation.

In a human trial for patients with AD, an endocannabinoid cream improved severity of itch and loss of sleep by an average of 60 percent among subjects. Twenty percent of subjects were able to stop their topical immunomodulators, 38 percent ceased using their oral antihistamines, and 33.6 percent no longer felt the need to maintain their topical steroid regimen by the end of the study.

The future of cannabis creams for eczema

For eczema patients, extra caution should be taken because a variety of known irritants are very prevalent in many “weed creams”. The indiscriminate addition of terpenes that can be irritating are often included in these formulations.

Special attention should be given to choosing a product to ensure that only non-irritating terpenes are included in the formula. Topicals should be chosen based on the profile of ingredients that are known to reduce pain, inflammation and irritation for the skin, not formulations that may have been developed for muscle and joint pain. Additionally, excess solvents from the manufacturing process could also be present.

With 29 states and counting having some form of legalization of medical marijuana, this means that there are at least 29 state regulatory schemes.

To further complicate things, hemp-based products (low THC varieties) can be purchased online and have virtually no regulatory oversight for potency, consistency or contaminants including pesticides and metals.

Incorrect dosing and inaccurate labeling has plagued the industry since inception. A recent study by Penn State University determined that up to 70 percent of online CBD products are inaccurately labeled.

Until clinical data is created for specific products, the best advice may be to pay special attention to the ingredient lists and make sure that products are tested by a third-party laboratory instead of the manufacturer themselves. State markets with dispensaries typically regulate testing, which is an added consumer protection compared to purchasing a product on the internet.

Cannabinoids represent an exciting prospect for the future of AD therapy. With measurable anti-itch, anti-pain, anti-microbial and anti-inflammatory properties, the effect of cannabinoids in patients with AD has already begun to be demonstrated.

Disclaimer: The information provided in this article has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). It is not medical advice. If you are considering making any changes to your lifestyle, diet or nutrition, you should consult with your doctor or other health care provider. Conflicts of interest statement: Helena Yardley, Ph.D. and Jon Fernandez, SVP are employees of Franklin BioScience, the manufacturer of Altus products. Peter Lio, M.D. is on the advisory board of Franklin BioScience.  

Resources

Palmer, C. N. A. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38, 441–446 (2006).Shrestha, S. et al. Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases. Adv. Ther.34, 1989–2006 (2017).Eckert, L. et al. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. J. Am. Acad. Dermatol. 77, 274–279.e3 (2017).Das, A. & Panda, S. Use of Topical Corticosteroids in Dermatology: An Evidence-based Approach. Indian J. Dermatol. 62, 237–250Weidinger, S., Baurecht, H. & Schmitt, J. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. Br. J. Dermatol. 177,999–1003 (2017).Sigurgeirsson, B. & Luger, T. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal – author response. Br. J. Dermatol.177, 1006–1006 (2017).Fitzcharles, M.-A., Baerwald, C., Ablin, J. & Hauser, W. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials. Schmerz 30, 47–61 (2016).Babson, K. A., Sottile, J. & Morabito, D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr. Psychiatry Rep. 19, 23 (2017).Baron, E. P. Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It’s Been. 885–916 (2000). doi:10.1111/head.12570O’Connell, B. K., Gloss, D. & Devinsk, O. Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav. 70, 341–348 (2016).Bíró, T., Tóth, B. I., Haskó, G., Paus, R. & Pacher, P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol. Sci. 30, 411–420 (2009).Matsuda, L. a, Lolait, S. J., Brownstein, M. J., Young, a C. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561–564 (1990).Lachenmeier, D. W. & Rehm, J. Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci. Rep. 5, 8126 (2015).Gable, R. S. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 99, 686–696 (2004).Hess, C., Krämer, M. & Madea, B. Topical application of THC containing products is not able to cause positive cannabinoid finding in blood or urine. Forensic Sci. Int. 272, 68–71 (2017).Theroux, Z. & Cropley, T. Cannabis and Dr Piffard—A Century Ahead of the Curve. JAMA Dermatology 152, 972 (2016).Tubaro, A. et al. Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins. Fitoterapia 81, 816–819 (2010).Kim, H. J. et al. Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model. Int. J. Dermatol.54, e401–e408 (2015).Caterina, M. J. TRP Channel Cannabinoid Receptors in Skin Sensation, Homeostasis, and In fl ammation. (2014).Elmariah, S. B. Adjunctive Management of Itch in Atopic Dermatitis. Dermatol. Clin. 35,373–394 (2017).Nam, G. et al. Selective cannabinoid receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model. Ann. Dermatol. 28, 22–29 (2016).Kupczyk, P., Reich, A. & Szepietowski, J. C. Cannabinoid system in the skin – A possible target for future therapies in dermatology. Exp. Dermatol. 18, 669–679 (2009).Russo, E. B. History of cannabis and its preparations in saga, science, and sobriquet. Chem. Biodivers. 4, 1614–1648 (2007).Ständer, S., Schmelz, M., Metze, D., Luger, T. & Rukwied, R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J. Dermatol. Sci. 38, 177–188 (2005).Richardson, J. D., Kilo, S. & Hargreaves, K. M. Cannabinoids reduce hyperalgesia and imflammation via interaction with peripheral CB receptors. Pain 75, 111–119 (1998).Ellington, H. C., Cotter, M. A., Cameron, N. E. & Ross, R. A. The effect of cannabinoids on capsaicin-evoked calcitonin gene- related peptide ( CGRP ) release from the isolated paw skin of diabetic and non-diabetic rats. 42, 966–975 (2002).Appendino, G. et al. Antibacterial Cannabinoids from Cannabis sativa : A Structure – Activity Study. J. Nat. Prod. 71, 1427–1430 (2008).Gaffal, E., Cron, M., Glodde, N. & Tüting, T. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy Eur. J. Allergy Clin. Immunol. 68, 994–1000 (2013).Ibrahim, M. M. et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. 102, 3093–3098 (2005).LaBuda, C. J., Koblish, M. & Little, P. J. Cannabinoid CB2 receptor agonist activity in the hindpaw incision: Model of postoperative pain. Eur. J. Pharmacol. 527, 172–174 (2005).Johanek, L. M. & Simone, D. A. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain 109, 432–442 (2004).Gaffal, E., Glodde, N., Jakobs, M., Bald, T. & T??ting, T. Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis. Exp. Dermatol. 23, 401–406 (2014).Dvorak, M., Watkinson, a, McGlone, F. & Rukwied, R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm. Res. 52, 238–245 (2003).Bonn-Miller, M. O. et al. Labeling Accuracy of Cannabidiol Extracts Sold Online. Jama318, 1708 (2017).